Report Library
All Reports
2015 HER2-Targeted Breast Cancer Infographic - BioMedTracker
April 02, 2015
The advent of Herceptin (trastuzumab, Genentech/Roche) changed breast cancer treatment for patients with HER2+ disease. Today, the
majority of patients with HER2+ breast cancer receive Herceptin in the (neo)adjuvant or metastatic settings, and sponsors of other approved
and experimental agents that target HER2+ hope to further improve patient outcomes. In this two-page infographic, we provide a general
overview of the HER2-targeted treatment landscape, with a focus on breast cancer.
To download the infographic, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
To download the infographic, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
| Indications Covered: | Breast Cancer |
Additional Resources:
- 2015 AML Infographic - BioMedTracker
- 2015 Post-Report: Future of Genomic Medicine VIII
- Pediatric Acute Leukemias (AML/ALL) KOL Interview
- CDK Inhibitors Infographic
- Citeline Trialscapes: Breast Cancer Second Line or Greater Therapies, Phase III
- Citeline Trialscapes: Breast Cancer First Line Therapies, Phase III